Source link : https://newshealth.biz/health-news/adding-polivy-to-standard-of-care-boosts-survival-in-relapsed-refractory-dlbcl/
(MedPage Today) — Adding polatuzumab vedotin (Polivy) to standard-of-care treatment significantly improved overall survival (OS) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), the phase III POLARGO trial showed… Source link : https://www.medpagetoday.com/meetingcoverage/eha/116098 Author : Publish date : 2025-06-16 19:39:00 Copyright for syndicated content belongs to the linked Source.
The post Adding Polivy to Standard of Care Boosts Survival in Relapsed/Refractory DLBCL first appeared on News Health.
—-
Author : News Health
Publish date : 2025-06-16 19:39:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8